RTP Mobile Logo
Beyond the Guidelines: Investigator Perspectives on the Current and Future Role of PARP Inhibition in the Management of Ovarian Cancer
Released May 2018

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Robert L Coleman, Joyce F Liu, Mansoor Raza Mirza and Kathleen Moore. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

    The American Cancer Society estimates that in 2018, more than 14,000 individuals will die of ovarian cancer (OC), accounting for nearly half of the deaths attributable to all gynecologic cancers. For this reason, significant financial and intellectual resources have been invested over the past few decades in attempts to better understand the natural history of the disease, identify genetic and other factors responsible for its proliferation and develop novel therapies with the potential to significantly improve outcomes for patients. Perhaps the largest recent advance in OC has been the introduction of PARP inhibitors into the therapeutic milieu. However, the paradigm shift brought forth by the availability of PARP inhibitors has significant ramifications for practicing clinicians who must now confront a variety of practical issues, and uncertainties with regard to the safe and efficacious use of these agents persist.

    These video proceedings from a CME symposium held during the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer explore the perspectives of leading medical oncology and gynecologic oncology investigators regarding a number of common clinical scenarios in the context of key data sets. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers with the optimal incorporation of PARP inhibition into OC treatment algorithms.


    • Compare and contrast the diagnostic and therapeutic recommendations made by gynecologic cancer clinical investigators for patients with OC, and use this information to guide the integration of PARP inhibitors into the care of appropriate individuals.
    • Appraise available guideline recommendations and consensus statements regarding the indications and evidence-based modalities for genetic testing in OC, and use the results of these assessments to guide long-term treatment planning.
    • Appreciate available clinical trial data with, approved indications for and common toxicities resulting from the use of FDA-endorsed PARP inhibitors for patients with OC to safely integrate these agents into routine clinical practice.
    • Consider available clinical trial data with PARP inhibitors as maintenance therapy for recurrent, platinum-sensitive OC, and develop strategies to incorporate this approach into current management algorithms.
    • Develop an understanding of the mechanisms of action, available data and potential clinical roles of other investigational PARP inhibitors in preparation for their potential introduction into future OC clinical practice.
    • Recognize the biologic rationale for, available data with and ongoing investigations of PARP inhibitors in combination with chemotherapy, biologic therapy and immunotherapy, and refer appropriate patients for clinical trial participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Robert L Coleman, MD
    Professor and Vice Chair, Clinical Research
    Ann Rife Cox Chair in Gynecology
    Department of Gynecologic Oncology and Reproductive Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Genentech BioOncology, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Contracted Research: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech BioOncology, Janssen Biotech Inc, Merck, Roche Laboratories Inc.

    Joyce F Liu, MD, MPH
    Assistant Professor of Medicine, Gynecologic Oncology Program
    Susan F Smith Center for Women’s Cancers
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Tesaro Inc; Consulting Agreement: AstraZeneca Pharmaceuticals LP.

    Mansoor Raza Mirza, MD
    Medical Director, Nordic Society of Gynecologic Oncology
    Chief Oncologist, Department of Oncology
    Rigshospitalet, Copenhagen University Hospital
    Copenhagen, Denmark

    Board of Directors: Karyopharm Therapeutics, Metamark Genetics Inc, Sera Prognostics; Consulting Agreements: Advaxis Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Cerulean Pharma Inc, Clovis Oncology, Genmab, Karyopharm Therapeutics, Novocure, Pfizer Inc, Roche Laboratories Inc, Tesaro Inc; Paid Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Pfizer Inc, Roche Laboratories Inc, Tesaro Inc.

    Kathleen Moore, MD
    Jim and Christy Everest Endowed Chair in Cancer Research
    Director, Oklahoma TSET Phase I Program
    Stephenson Cancer Center
    Associate Professor, Section of Gynecologic Oncology
    Director, Gynecologic Oncology Fellowship
    Department of Obstetrics and Gynecology
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Myriad Genetic Laboratories Inc and Tesaro Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: May 2018
    Expiration date: May 2019

Acknowledge and close